Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present BioCardia, Inc. (OTC: BCDA).

Full DD Report for BCDA

You must become a subscriber to view this report.


Recent News from (OTC: BCDA)

BioCardia reports Q1 results
BioCardia ( OTCQB:BCDA ): Q1 EPS of -$0.09 More news on: BioCardia, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 11 2018 08:02
BioCardia, Inc. Reports First Quarter 2018 Financial Results And Business Highlights
SAN CARLOS, Calif. , May 11, 2018 /PRNewswire/ --  BioCardia®, Inc.  [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, filed its 10-Q for the three months ended March 31, 2018 with the Securities and Exc...
Source: PR Newswire
Date: May, 11 2018 08:00
Centers for Medicare and Medicaid Services Approves Reimbursement for BioCardia's CardiAMP Cell Therapy in Pivotal Clinical Trial Studying Second Indication in Chronic Myocardial Ischemia
BioCardia®, Inc ., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved national reimbursement coverage for the CardiAMP Chronic Myocardial I...
Source: Business Wire
Date: May, 10 2018 07:00
BioCardia Receives New Potency Assay Patent, Providing Further Protection to Autologous Cell Therapy Programs in Heart Failure and Refractory Angina
SAN CARLOS, Calif. , April 25, 2018 /PRNewswire/ -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of United States Patent No. 9,945,854 relating to methods of measuring the...
Source: PR Newswire
Date: April, 25 2018 07:00
BioCardia Presents at Alliance for Regenerative Medicine's (ARM's) Annual Cell & Gene Therapy Investor Day
SAN CARLOS, Calif. , April 18, 2018 /PRNewswire/ -- BioCardia®, Inc., [OTC: BCDA] a leader in cardiovascular regenerative medicine, today announced that it was among the companies providing presentations at the Alliance for Regenerative Medicine's (ARM's) 6 th Annual Cell &...
Source: PR Newswire
Date: April, 18 2018 07:00
Phase III CardiAMP Heart Failure Trial Featured in American Heart Journal
SAN CARLOS, Calif. , April 9, 2018 /PRNewswire/ -- BioCardia®, Inc., [OTC: BCDA] a leader in cardiovascular regenerative medicine, today announced the publication of the Phase III CardiAMP Heart Failure Trial design paper in the American Heart Journal. Titled "The CardiAMP Hea...
Source: PR Newswire
Date: April, 09 2018 08:30
BioCardia reports Q4 results
BioCardia ( OTCQB:BCDA ): Q4 EPS of -$0.09 More news on: BioCardia, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 21 2018 08:13
BioCardia, Inc. Reports Fourth Quarter 2017 Financial Results and Business Highlights
BioCardia®, Inc.  [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announced it filed its annual 10-K for the year ended December 31, 2017 with the Securities and Exchange Commission on Friday, March 16, 2018. BioCa...
Source: Business Wire
Date: March, 21 2018 08:00
CardiAMP Cell Therapy Receives FDA Approval for Pivotal Trial in Chronic Myocardial Ischemia
BioCardia®, Inc.  [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption for the CardiAMP Chronic Myocardial Is...
Source: Business Wire
Date: January, 29 2018 19:51
BioCardia Submits Clinical Trial to FDA for New Indication of Chronic Myocardial Ischemia for CardiAMP Cell Therapy
BioCardia®, Inc.  [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported filing a second Investigational Device Exemption with the Food and Drug Administration (FDA) for the CardiAMP Chronic Myocardial Ischemia...
Source: Business Wire
Date: January, 05 2018 06:00

 


About BioCardia, Inc. (OTC: BCDA)

Logo for BioCardia, Inc. (OTC: BCDA)

BioCardia, Inc. is a clinical stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. Its lead therapeutic candidate is the CardiAMP cell therapy system and its second therapeutic candidate is the CardiALLO cell therapy system. BioCardia is headquartered in San Carlos, California.

 

Contact Information

 

 

Current Management

  • Peter Alan Altman / CEO, President
  • David McClung / CFO
  • Henricus Johannes Duckers / CMO
  • Ivone Chanu / Manager
  • Richard Thomas Allen / Other
  • Simon H. Stertzer / Chairman, Independent Director
  • Peter Alan Altman /
  • Fernando L. Fernandez / Independent Director, Audit Committee Member
  • Richard Pfenniger, Jr. / Independent Director, Compensation Committee Member
  • Richard M. Krasno / Independent Director
  • Jay M. Moyes / Independent Director, Audit Committee Member, Compensation Committee Member
  • Thomas Quertermous / Independent Director
  • Allan Roger Tessler / Independent Director, Audit Committee Member

Current Share Structure

  • Market Cap: $74,562,175 - 03/15/2018
  • Authorized: 100,000,000 - 03/12/2018
  • Issue and Outstanding: 38,237,013 - 03/12/2018

 


Recent Filings from (OTC: BCDA)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: April, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 12 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: February, 05 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 09 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 07 2017
All other definitive information statements
Filing Type: DEF 14CFiling Source: edgar
Filing Date: October, 10 2017
Preliminary proxy statement containing all other information
Filing Type: PRE 14CFiling Source: edgar
Filing Date: September, 26 2017

 

 


Daily Technical Chart for (OTC: BCDA)

Daily Technical Chart for (OTC: BCDA)


Stay tuned for daily updates and more on (OTC: BCDA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BCDA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BCDA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BCDA and does not buy, sell, or trade any shares of BCDA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/